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GebFra Science | Letter to the EditorWe read with great interest the article of Kacan et al. entitled
“Everolimus as an mTOR Inhibitor Suppresses Endometriotic Im-
plants: an Experimental Rat Study” [1] published in your journal.
The authors surgically induced endometriosis by the autotrans-
plantation of uterine tissue in the peritoneal cavity of 24 rats. The
animals were randomized in three groups, receiving oral everoli-
mus, oral anastrozole, or intravenous saline solution for 14 days.
Histological evaluation was done by the endometriosis score (ac-
cording to Keenan et al. [2]) and immunohistochemical examina-
tion was performed by using antibodies against vascular endothe-
lial growth factor (VEGF), CD117 and BAX. The post-treatment
analysis of endometriotic implants revealed that anastrozole and
everolimus succeeded in significantly decreasing their growth
and size with no difference in histological and immunohistochem-
ical results between the two drugs. The authors noted at histology
that the number of ovarian follicles was not negatively altered by
everolimus, differently from anastrozole that, as evidenced in lit-
erature, tends to decrease it [3].
The rational of the study is based on the evidence of the pivotal
role of mTOR in angiogenesis and growth of endometriotic im-
plants [4]. The results of the therapy are in line with a previous
study performed on the animal model [5], in which Leconte et al.
found that also the administration of temsirolimus (intraperito-
neal 3mg/kg), another mTor inhibitor, for 2 weeks led to signifi-
cant decreases in endometriosis implants growth.
Although the authors should be congratulated for their labora-
tory findings, we would like to raise some concerns on the admin-
istration of mTor inhibitors, and in particular everolimus, in theBarra F and Ferrero S. mTor Inhibitors for… Geburtsh Frauenheilk 2018; 78: 283–284clinical treatment of endometriosis. Everolimus is approved by
Food and Drug Administration (FDA) for the treatment of ad-
vanced tumors, such as advanced kidney cancer, progressive or
metastatic pancreatic or gastrointestinal neuroendocrine tumors,
and it is currently being also evaluated in gynecological cancers.
Moreover, its use is indicated for immunosuppression after solid
organ transplant [6].
Although in oncologic setting it has been reported that pa-
tients with specific mutations (i.e. PIK3A, PTEN) tend to have high-
er benefit receiving mTor pathway inhibitors, a first non-negligible
problem is that there are no validated predictive biomarkers for
patientsʼ selection and for monitoring drug efficacy [7]. A second
concern is related to the fact that in the experiment endometri-
otic implants were surgically induced only in peritoneum of rats,
and not in other localizations. Thus, it appears unlikely that drugs
acting on angiogenesis-related pathways, such as mTor, may treat
the symptoms caused by large nodules of deep infiltrating endo-
metriosis (DIE), which are mainly composed of fibromuscular tis-
sue, and may have already been present for some years.
More importantly, drugs targeting mTor pathway may cause
adverse effects [8], including a large variety of metabolic, hema-
tological, respiratory, renal and dermatological toxicities. These
sometime serious side effects explain the notable rate of drug dis-
continuation in clinical trials for advanced cancer. Although some
of them, such as oral stomatitis (30–60% of patients) or pneumo-
nitis, seem to increase with the dosage of the drug, the majority
are idiosyncratic and unpredictable, and may also occur from days
to years after the beginning of the therapy. These adverse effects283
GebFra Science | Letter to the Editormay be tolerable in oncological therapy, where the primary end-
points are disease-free survival and overall survival, but it appears
difficult to accept them in young women with endometriosis
where the goal is improving the quality of life. In fact, endome-
triosis is a chronic benign disease that requires a long-term ther-
apy combining clinical efficacy (preventing recurrence, control-
ling pain symptoms) with acceptable costs and toxicity. Given this
background, it seems unlikely that everolimus may have a relevant
role in the future treatment of women with endometriosis.
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